Active Ingredient History

NOW
  • Now
Tapentadol is the first US FDA-approved centrally acting analgesic having both μ-opioid receptor agonist and noradrenaline (norepinephrine) reuptake inhibition activity with minimal serotonin reuptake inhibition. Tapentadol is indicated for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate, neuropathic pain associated with diabetic peripheral neuropathy (DPN) severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.   NCATS

More Chemistry

Drug Pricing (per unit)

Australia

$0.3004 - $1.0306

United States

$1.9957 - $30.0171
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

3-((1r,2r)-3-(dimethylamino)-1-ethyl-2-methylpropyl)phenol | bn-200 | cg5503 | cg 5503 | cg-5503 | nucynt | nucynta | nucynta er | palexia | tapentadol | tapentadol hcl | tapentadol hydrochloride

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue